RNC Capital Management LLC trimmed its stake in Kenvue Inc. (NYSE:KVUE – Free Report) by 8.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,172,166 shares of the company’s stock after selling 101,504 shares during the period. RNC Capital Management LLC owned about 0.06% of Kenvue worth $25,237,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also bought and sold shares of KVUE. Envestnet Asset Management Inc. acquired a new stake in Kenvue in the second quarter valued at $1,387,000. Cetera Investment Advisers acquired a new stake in Kenvue in the second quarter valued at $416,000. Citigroup Inc. acquired a new stake in Kenvue in the second quarter valued at $57,000. Osaic Holdings Inc. bought a new stake in Kenvue during the second quarter valued at $144,000. Finally, Northern Trust Corp bought a new stake in Kenvue during the second quarter valued at $1,244,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.
Kenvue Stock Performance
NYSE:KVUE opened at $21.45 on Thursday. The company has a current ratio of 1.12, a quick ratio of 0.78 and a debt-to-equity ratio of 0.69. Kenvue Inc. has a 52 week low of $17.82 and a 52 week high of $27.80. The firm has a 50-day moving average price of $20.00 and a two-hundred day moving average price of $20.25.
Kenvue Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Wednesday, February 28th. Stockholders of record on Wednesday, February 14th were paid a dividend of $0.20 per share. The ex-dividend date was Tuesday, February 13th. This represents a $0.80 annualized dividend and a dividend yield of 3.73%.
Wall Street Analysts Forecast Growth
A number of analysts have commented on KVUE shares. The Goldman Sachs Group assumed coverage on shares of Kenvue in a research report on Friday, March 1st. They set a “neutral” rating and a $20.00 price objective on the stock. UBS Group increased their price objective on shares of Kenvue from $20.00 to $23.00 and gave the stock a “neutral” rating in a research report on Tuesday, December 19th. Royal Bank of Canada cut their price objective on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a research report on Friday, February 9th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a research report on Friday, February 9th. Seven investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $25.42.
View Our Latest Report on Kenvue
Kenvue Company Profile
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands.
Read More
- Five stocks we like better than Kenvue
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Best Bear Market Funds: Top 3 Investment Options to Consider
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Is DraftKings A Good Bet Ahead of Q1 Earnings?
- Investing In Automotive Stocks
- Mid-Cap Stocks to Outperform the Market This Cycle
Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE – Free Report).
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.